Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A drug candidate being developed by Israeli drug company BioLineRx as a treatment for schizophrenia has produced data in preclinical studies suggesting that the drug retains the efficacy of currently available antipsychotic drugs while achieving a much higher safety profile.
Subscribe to our email newsletter
In April, BioLineRx began phase I clinical trials to evaluate the safety and determine the pharmacokinetic profile of the compound, BL-1020, in humans.
“We continue to be very encouraged by the safety and efficacy results for BL-1020 in preclinical studies and are eager to see the data from our currently ongoing phase I clinical trial, expected in the third quarter of this year,” commented Dr Morris Laster, CEO of BioLineRx.
Schizophrenia is a major debilitating illness that affects approximately eight million people worldwide. Currently, both extrapyramidal and metabolic side effects, which significantly limit patient compliance, are a major obstacle in the treatment of the disorder.